On November 18th, the Ministry of Health and Welfare and the Ministry of Economic Affairs jointly held the "2025 National Pharmaceutical Technology Research and Development Award" ceremony at the National Biotechnology Research Park. Ever-Supreme's "CAR001-Allogeneic mRNA Gene Transplantation Multi-Targeted CAR-γδ T Cell Therapy for Solid Tumors" won the Bronze Award in the Pharmaceutical Category. This multi-target immunotherapy, which targets allogeneic, non-viral mRNA editing, is specifically designed for refractory solid tumors such as colorectal cancer, triple-negative breast cancer, glioblastoma, and non-small cell lung cancer. Its outstanding achievements in the research and development field were recognized by the judges. It is hoped that with the continued support and promotion of various units, they can work together to create new value for biotechnology and pharmaceutical brands and steadily move towards the goal of bringing better health to the people of Taiwan.
